{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:48:19Z","timestamp":1793504899480,"version":"4.5.0"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.intimp.2025.115986","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:30:00Z","timestamp":1765528200000},"page":"115986","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Immune escape in colorectal cancer: Mechanisms and challenges of immune checkpoint inhibitor resistance"],"prefix":"10.1016","volume":"169","author":[{"given":"Mohammad","family":"Yousefi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danial Gharaie","family":"Amirabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Javan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arezou","family":"Khosrojerdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2025.115986_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115986_bb0010","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.3390\/cancers16112005","article-title":"Microsatellite instability testing and prognostic implications in colorectal Cancer","volume":"16","author":"Ho","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2025.115986_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1178772","article-title":"Concordance between microsatellite instability and mismatch repair protein expression in colorectal cancer and their clinicopathological characteristics: a retrospective analysis of 502 cases","volume":"13","author":"Ye","year":"2023","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115986_bb0020","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00675","article-title":"Prevalence and Clinical Implications of Mismatch Repair-Proficient Colorectal Cancer in Patients With Lynch Syndrome","author":"Ranganathan","year":"2023","journal-title":"JCO Precision Oncology"},{"issue":"12","key":"10.1016\/j.intimp.2025.115986_bb0025","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.3390\/cancers15123097","article-title":"Immuno-contexture and immune checkpoint molecule expression in mismatch repair proficient colorectal carcinoma","volume":"15","author":"Giacomelli","year":"2023","journal-title":"Cancers"},{"issue":"23","key":"10.1016\/j.intimp.2025.115986_bb0030","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal Cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.intimp.2025.115986_bb0035","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/jso.27079","article-title":"Colorectal cancer","volume":"126","author":"Paty","year":"2022","journal-title":"J. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115986_bb0040","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"9209","key":"10.1016\/j.intimp.2025.115986_bb0045","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.intimp.2025.115986_bb0050","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal Cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.intimp.2025.115986_bb0055","first-page":"2509","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le Dung","year":"2025","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.intimp.2025.115986_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1160949","article-title":"Progress of research on molecular targeted therapies for colorectal cancer","volume":"14","author":"Huang","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115986_bb0065","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1634\/theoncologist.2017-0203","article-title":"A comprehensive review of sequencing and combination strategies of targeted agents in metastatic colorectal Cancer","volume":"23","author":"Ciombor","year":"2018","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.intimp.2025.115986_bb0070","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1186\/s12885-020-07656-w","article-title":"Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis","volume":"20","author":"Rumpold","year":"2020","journal-title":"BMC Cancer"},{"issue":"6127","key":"10.1016\/j.intimp.2025.115986_bb0075","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.intimp.2025.115986_bb0080","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.tips.2023.01.003","article-title":"Metastatic colorectal cancer: mechanisms and emerging therapeutics","volume":"44","author":"Shin","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2025.115986_bb0085","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2025.115986_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"issue":"17","key":"10.1016\/j.intimp.2025.115986_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174426","article-title":"The role of oncogenes and redox Signaling in the regulation of PD-L1 in Cancer","volume":"13","author":"Glorieux","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.intimp.2025.115986_bb0100","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol. Rev."},{"issue":"S1","key":"10.1016\/j.intimp.2025.115986_bb0105","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.2022.36.S1.R3699","article-title":"Investigating CTLA-4 binding to generate novel small-molecule inhibitor","volume":"36","author":"Khoroshilov","year":"2022","journal-title":"FASEB J."},{"key":"10.1016\/j.intimp.2025.115986_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111055","article-title":"Immunotherapy for colorectal cancer: rational strategies and novel therapeutic progress","volume":"126","author":"Rastin","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"10304","key":"10.1016\/j.intimp.2025.115986_bb0115","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.intimp.2025.115986_bb0120","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in Cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115986_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008409","article-title":"Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial","volume":"12","author":"Lenz","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2025.115986_bb0130","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007364","article-title":"Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors","volume":"12","author":"Khushalani","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2025.115986_bb0135","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O\u2019Donnell","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115986_bb0140","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2025.115986_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2025.115986_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1490129","article-title":"Revisiting immune checkpoint inhibitors: new strategies to enhance efficacy and reduce toxicity","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115986_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1264327","article-title":"Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors","volume":"14","author":"Roy","year":"2023","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115986_bb0160","first-page":"451","article-title":"Immune checkpoint inhibitors: breakthroughs in cancer treatment","volume":"21","author":"Kong","year":"2024","journal-title":"Cancer Biology & Medicine"},{"issue":"1","key":"10.1016\/j.intimp.2025.115986_bb0190","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1186\/s12913-023-10037-1","volume":"23","author":"Zhu","year":"2023","journal-title":"BMC Health Serv. Res."},{"issue":"2","key":"10.1016\/j.intimp.2025.115986_bb0215","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal Cancer: the phase II CheckMate 142 study","volume":"40","author":"Lenz","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"10476","key":"10.1016\/j.intimp.2025.115986_bb0390","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andr\u00e9","year":"2025","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.intimp.2025.115986_bb0370","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008689","article-title":"Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"12","author":"Overman","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.intimp.2025.115986_bb0205","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1007\/s00262-021-02986-5","article-title":"A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186","volume":"70","author":"Herting","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.intimp.2025.115986_bb0300","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","article-title":"Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Antoniotti","year":"2022","journal-title":"Lancet Oncol."},{"issue":"22","key":"10.1016\/j.intimp.2025.115986_bb0305","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1200\/JCO.23.02728","article-title":"Upfront fluorouracil, leucovorin, oxaliplatin, and irinotecan plus bevacizumab with or without atezolizumab for patients with metastatic colorectal Cancer: updated and overall survival results of the ATEZOTRIBE study","volume":"42","author":"Antoniotti","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115986_bb0290","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41591-023-02497-z","article-title":"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial","volume":"29","author":"Thibaudin","year":"2023","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.intimp.2025.115986_bb0355","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jamaoncol.2022.7845","article-title":"Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal Cancer and disease progression with prior chemotherapy: a phase 1 nonrandomized clinical trial","volume":"9","author":"Fakih","year":"2023","journal-title":"JAMA Oncol."},{"issue":"14","key":"10.1016\/j.intimp.2025.115986_bb0220","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.21.02583","article-title":"Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine\u2013DNA Methyltransferase\u2013Silenced Metastatic Colorectal Cancer: The MAYA Trial","volume":"40","author":"Morano","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115986_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100594","article-title":"CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial","volume":"7","author":"Saunders","year":"2022","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.intimp.2025.115986_bb0395","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006136","article-title":"Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors","volume":"11","author":"Lemech","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2025.115986_bb0330","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115986_bb0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13148-021-01226-y","article-title":"Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis","volume":"14","author":"Kuang","year":"2022","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.intimp.2025.115986_bb0195","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2022.03.017","article-title":"Pembrolizumab and maraviroc in refractory mismatch repair proficient\/microsatellite-stable metastatic colorectal cancer \u2013 the PICCASSO phase I trial","volume":"167","author":"Haag","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.intimp.2025.115986_bb0400","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/s41416-021-01368-z","article-title":"A phase 1\/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer","volume":"124","author":"Kim","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2025.115986_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100559","article-title":"MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer\u2606","volume":"7","author":"Tabernero","year":"2022","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.intimp.2025.115986_bb0325","doi-asserted-by":"crossref","first-page":"2149040","DOI":"10.1001\/jamanetworkopen.2021.49040","article-title":"Assessment of capecitabine and bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal Cancer: a randomized clinical trial","volume":"5","author":"Mettu","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"7","key":"10.1016\/j.intimp.2025.115986_bb0310","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/annonc\/mdz113","article-title":"Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors","volume":"30","author":"Hellmann","year":"2019","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115986_bb0280","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1158\/1078-0432.CCR-20-2474","article-title":"Phase II single-arm study of durvalumab and Tremelimumab with concurrent radiotherapy in patients with mismatch repair\u2013proficient metastatic colorectal Cancer","volume":"27","author":"Segal","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2025.115986_bb0275","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005640","article-title":"Phase I\/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer","volume":"11","author":"Monge","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"6349","key":"10.1016\/j.intimp.2025.115986_bb0170","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.intimp.2025.115986_bb0175","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/cas.15650","article-title":"Pembrolizumab in Asian patients with microsatellite-instability-high\/mismatch-repair-deficient colorectal cancer","volume":"114","author":"Yoshino","year":"2023","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.intimp.2025.115986_bb0180","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol."},{"issue":"17","key":"10.1016\/j.intimp.2025.115986_bb0185","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1158\/1078-0432.CCR-21-0557","article-title":"FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H\/dMMR advanced unresectable or metastatic colorectal carcinoma","volume":"27","author":"Casak","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.intimp.2025.115986_bb0200","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/s41416-021-01368-z","article-title":"A phase 1\/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer","volume":"124","author":"Kim","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"14","key":"10.1016\/j.intimp.2025.115986_bb0210","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.7150\/ijbs.64077","article-title":"Immunotherapy in colorectal cancer: current achievements and future perspective","volume":"17","author":"Fan","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"10","key":"10.1016\/j.intimp.2025.115986_bb0230","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007235","article-title":"Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer","volume":"11","author":"Akce","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2025.115986_bb0235","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1039\/D3MD00655G","article-title":"Progress in small-molecule inhibitors targeting PD-L1","volume":"15","author":"Xu","year":"2024","journal-title":"RSC Medicinal Chemistry"},{"issue":"6","key":"10.1016\/j.intimp.2025.115986_bb0240","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1021\/acs.jmedchem.4c00102","article-title":"Discovery of novel PD-L1 small-molecular inhibitors with potent in vivo anti-tumor immune activity","volume":"67","author":"Liu","year":"2024","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.intimp.2025.115986_bb0245","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1021\/acsmedchemlett.4c00042","article-title":"Nonsymmetrically substituted 1,1\u2032-biphenyl-based small molecule inhibitors of the PD-1\/PD-L1 interaction","volume":"15","author":"Hec-Ga\u0142\u0105zka","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.intimp.2025.115986_bb0250","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s40265-017-0782-5","article-title":"Durvalumab: First Global Approval","volume":"77","author":"Syed","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2025.115986_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114519","article-title":"Exosomal PD-L1 in non-small cell lung Cancer: implications for immune evasion and resistance to immunotherapy","volume":"155","author":"Tarin","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115986_bb0260","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1002\/ijc.33966","article-title":"Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high\/mismatch repair-deficient or -mutated metastatic or unresectable colorectal cancer","volume":"150","author":"Oh","year":"2022","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.intimp.2025.115986_bb0265","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1158\/1078-0432.CCR-21-0163","article-title":"Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases","volume":"27","author":"Marie","year":"2021","journal-title":"Clinical Cancer Research"},{"issue":"12","key":"10.1016\/j.intimp.2025.115986_bb0270","doi-asserted-by":"crossref","first-page":"2346094","DOI":"10.1001\/jamanetworkopen.2023.46094","article-title":"Liver metastases and immune checkpoint inhibitor efficacy in patients with refractory metastatic colorectal Cancer: a secondary analysis of a randomized clinical trial","volume":"6","author":"Chen","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"8","key":"10.1016\/j.intimp.2025.115986_bb0285","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005332","article-title":"Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)","volume":"10","author":"Johnson","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2025.115986_bb0295","doi-asserted-by":"crossref","DOI":"10.1002\/bio.4747","article-title":"Development of time-resolved fluoroimmunoassay with enhanced fluorescence reaction for the quantitation of atezolizumab in plasma","volume":"39","author":"Darwish","year":"2024","journal-title":"Luminescence"},{"key":"10.1016\/j.intimp.2025.115986_bb0320","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2023.01.023","article-title":"Clinical and exploratory biomarker findings from the MODUL trial (cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer","volume":"184","author":"Ducreux","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.intimp.2025.115986_bb0335","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in Cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2025.115986_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103663","article-title":"Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: a 2022 update","volume":"173","author":"Boukouris","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"16_suppl","key":"10.1016\/j.intimp.2025.115986_bb0345","doi-asserted-by":"crossref","first-page":"15556","DOI":"10.1200\/JCO.2022.40.16_suppl.e15556","article-title":"Nivolumab with ipilimumab for MSI-H colorectal cancer with liver metastases","volume":"40","author":"Michalaki","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.intimp.2025.115986_bb0350","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2023.41.16_suppl.3584","article-title":"A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable colorectal cancer","volume":"41","author":"Koenig","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115986_bb0360","series-title":"Characterization of a Novel Anti-Human Lymphocyte Activation Gene 3 (LAG-3) Antibody for cancer Immunotherapy, MAbs","first-page":"1139","author":"Yu","year":"2019"},{"issue":"16","key":"10.1016\/j.intimp.2025.115986_bb0365","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1016\/j.cell.2024.07.004","article-title":"Anti-LAG-3 boosts CD8 T cell effector function","volume":"187","author":"Kureshi","year":"2024","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.intimp.2025.115986_bb0375","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.3390\/biomedicines12122717","article-title":"The functional role and prognostic significance of TIM-3 expression on NK cells in the diagnostic bone marrows in acute myeloid Leukemia","volume":"12","author":"Sun","year":"2024","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.intimp.2025.115986_bb0380","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.molmed.2024.01.004","article-title":"TIM-3 inhibitors: a promising strategy for tumor immunotherapy","volume":"30","author":"Lu","year":"2024","journal-title":"Trends Mol. Med."},{"issue":"13","key":"10.1016\/j.intimp.2025.115986_bb0385","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","article-title":"Phase I\/Ib clinical trial of Sabatolimab, an anti-TIM-3 antibody, alone and in combination with Spartalizumab, an anti-PD-1 antibody","volume":"27","author":"Curigliano","year":"2021","journal-title":"Advanced Solid Tumors, Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.intimp.2025.115986_bb0405","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1002\/1878-0261.70023","article-title":"Multi-omic characterization of consensus molecular subtype 1 (CMS1) colorectal cancer with dampened immune response improves precision medicine","volume":"19","author":"Concetti","year":"2025","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.intimp.2025.115986_bb0410","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejca.2019.09.008","article-title":"The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications","volume":"123","author":"Soldevilla","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2025.115986_bb0415","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1007\/s11864-024-01282-5","article-title":"From subtypes to solutions: integrating CMS classification with precision therapeutics in colorectal cancer","volume":"25","author":"Ding","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115986_bb0420","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70521","article-title":"Enrichment of Cancer-associated fibroblasts, macrophages, and up-regulated TNF-\u03b1 Signaling in the tumor microenvironment of CMS4 colorectal peritoneal metastasis","volume":"14","author":"H\u00f8ye","year":"2025","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.intimp.2025.115986_bb0425","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.gendis.2019.10.013","article-title":"Molecular subtypes of colorectal cancer: an emerging therapeutic opportunity for personalized medicine","volume":"8","author":"Singh","year":"2021","journal-title":"Genes & Diseases"},{"issue":"1","key":"10.1016\/j.intimp.2025.115986_bb0430","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s42003-022-03884-x","article-title":"Genetic and microenvironmental intra-tumor heterogeneity impacts colorectal cancer evolution and metastatic development","volume":"5","author":"Sobral","year":"2022","journal-title":"Communications Biology"},{"issue":"7467","key":"10.1016\/j.intimp.2025.115986_bb0435","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nature12625","article-title":"The causes and consequences of genetic heterogeneity in cancer evolution","volume":"501","author":"Burrell","year":"2013","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.intimp.2025.115986_bb0440","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","article-title":"Intratumor heterogeneity: the Rosetta stone of therapy resistance","volume":"37","author":"Marusyk","year":"2020","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.intimp.2025.115986_bb0445","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.trecan.2023.05.001","article-title":"Clinical and translational relevance of intratumor heterogeneity","volume":"9","author":"Goyette","year":"2023","journal-title":"Trends in Cancer"},{"issue":"7568","key":"10.1016\/j.intimp.2025.115986_bb0450","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nature14971","article-title":"A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity","volume":"525","author":"Waclaw","year":"2015","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.intimp.2025.115986_bb0455","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1158\/0008-5472.CAN-10-3604","article-title":"Chromosomal instability confers intrinsic multidrug resistance","volume":"71","author":"Lee","year":"2011","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2025.115986_bb0460","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1053\/j.gastro.2008.07.076","article-title":"Genomic and epigenetic instability in colorectal cancer pathogenesis","volume":"135","author":"Grady","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2025.115986_bb0465","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s43018-021-00247-z","article-title":"Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer","volume":"2","author":"Westcott","year":"2021","journal-title":"Nature cancer"},{"key":"10.1016\/j.intimp.2025.115986_bb0470","series-title":"Low Neoantigen Expression and Poor T Cell Priming Underlie Early Immune Escape in cancer","author":"Westcott","year":"2020"},{"key":"10.1016\/j.intimp.2025.115986_bb0475","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-019-0654-6","article-title":"Evolving neoantigen profiles in colorectal cancers with DNA repair defects","volume":"11","author":"Rospo","year":"2019","journal-title":"Genome Med."},{"key":"10.1016\/j.intimp.2025.115986_bb0480","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.21303","article-title":"Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis","volume":"118","author":"Watson","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2025.115986_bb0485","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung Cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.intimp.2025.115986_bb0490","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1034\/j.1399-0039.2003.00020.x","article-title":"Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7\/TAP2 downregulation in MSI-negative tumors","volume":"61","author":"Cabrera","year":"2003","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.intimp.2025.115986_bb0495","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1356143","article-title":"TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer","volume":"6","author":"Ling","year":"2017","journal-title":"OncoImmunology"},{"issue":"12","key":"10.1016\/j.intimp.2025.115986_bb0500","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.humpath.2010.05.014","article-title":"Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer","volume":"41","author":"Kasajima","year":"2010","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.intimp.2025.115986_bb0505","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071760","article-title":"MHC class I downregulation in Cancer: underlying mechanisms and potential targets for Cancer immunotherapy","volume":"12","author":"Cornel","year":"2020","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.intimp.2025.115986_bb0510","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/s41416-024-02848-8","article-title":"DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors","volume":"131","author":"Amodio","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2025.115986_bb0515","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112638","article-title":"Mechanisms of immune escape and resistance to checkpoint inhibitor therapies in mismatch repair deficient metastatic colorectal cancers","volume":"13","author":"Amodio","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2025.115986_bb0520","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1042\/BST20210961","article-title":"Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance","volume":"50","author":"Balasubramanian","year":"2022","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.intimp.2025.115986_bb0525","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1038\/onc.2014.416","article-title":"Oncogenic KRAS signalling promotes the Wnt\/\u03b2-catenin pathway through LRP6 in colorectal cancer","volume":"34","author":"Lemieux","year":"2014","journal-title":"Oncogene"},{"issue":"7693","key":"10.1016\/j.intimp.2025.115986_bb0530","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"issue":"7693","key":"10.1016\/j.intimp.2025.115986_bb0535","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2025.115986_bb0540","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10238-023-01274-z","article-title":"WNT\/\u03b2-catenin regulatory roles on PD-(L)1 and immunotherapy responses","volume":"24","author":"Mortezaee","year":"2024","journal-title":"Clin. Exp. Med."},{"issue":"7","key":"10.1016\/j.intimp.2025.115986_bb0545","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.tips.2018.03.008","article-title":"Targeting Wnt\/\u03b2-catenin Signaling for Cancer immunotherapy","volume":"39","author":"Wang","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.intimp.2025.115986_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108921","article-title":"Intrinsic \u03b2-catenin signaling suppresses CD8+ T-cell infiltration in colorectal cancer","volume":"115","author":"Xue","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.intimp.2025.115986_bb0555","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41416-023-02483-9","article-title":"Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer - possible implications for immunotherapy","volume":"130","author":"Edin","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2025.115986_bb0560","series-title":"Drives Immune Evasion by Sensitizing Cytotoxic T-Cells to Activation-Induced Cell Death in Colorectal Cancer, Adv Sci (Weinh)","volume":"vol. 10(6)","author":"Liu","year":"2023"},{"key":"10.1016\/j.intimp.2025.115986_bb0565","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1112276","article-title":"Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer","volume":"13","author":"Ros","year":"2023","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.intimp.2025.115986_bb0570","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-015-0620-6","article-title":"Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy","volume":"16","author":"Angelova","year":"2015","journal-title":"Genome Biol."},{"key":"10.1016\/j.intimp.2025.115986_bb0575","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00619","article-title":"Intratumoral FoxP3+Helios+ regulatory T cells upregulating immunosuppressive molecules are expanded in human colorectal Cancer","volume":"8","author":"Syed Khaja","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115986_bb0580","article-title":"Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma","volume":"8","author":"Zhang","year":"2013","journal-title":"PloS One"},{"issue":"25","key":"10.1016\/j.intimp.2025.115986_bb0585","first-page":"3303","article-title":"Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma","volume":"18","author":"Sun","year":"2012","journal-title":"World J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115986_bb0590","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.4251\/wjgo.v16.i5.1690","article-title":"Mechanisms of myeloid-derived suppressor cell-mediated immunosuppression in colorectal cancer and related therapies","volume":"16","author":"Nie","year":"2024","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.intimp.2025.115986_bb0595","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1016\/j.cell.2021.07.029","article-title":"Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer","volume":"184","author":"Goc","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.115986_bb0600","article-title":"Colon carcinoma cell lines stimulate monocytes and lamina propria mononuclear cells to produce IL-10","volume":"110","author":"Kucharzik","year":"1997","journal-title":"Clinical & Experimental Immunology"},{"key":"10.1016\/j.intimp.2025.115986_bb0605","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1054\/bjoc.1999.1034","article-title":"Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection","volume":"82","author":"Heriot","year":"2000","journal-title":"Br. J. Cancer"},{"issue":"21","key":"10.1016\/j.intimp.2025.115986_bb0610","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.2217\/epi-2020-0267","article-title":"Epigenetic regulation of immune checkpoints and T cell exhaustion markers in tumor-infiltrating T cells of colorectal cancer patients","volume":"12","author":"Nair","year":"2020","journal-title":"Epigenomics"},{"issue":"10","key":"10.1016\/j.intimp.2025.115986_bb0615","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41416-019-0599-y","article-title":"Immune checkpoint inhibitors for the treatment of MSI-H\/MMR-D colorectal cancer and a perspective on resistance mechanisms","volume":"121","author":"Sahin","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.intimp.2025.115986_bb0620","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1158\/2159-8290.CD-20-0987","article-title":"CD4 T cell\u2013dependent rejection of beta-2 microglobulin null mismatch repair\u2013deficient tumors","volume":"11","author":"Germano","year":"2021","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.intimp.2025.115986_bb0625","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.intimp.2025.115986_bb0630","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2025.115986_bb0635","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jhep.2020.08.010","article-title":"Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma","volume":"74","author":"Kim","year":"2021","journal-title":"J. Hepatol."},{"issue":"19","key":"10.1016\/j.intimp.2025.115986_bb0640","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.3390\/cancers13194906","article-title":"Combination immunotherapies to overcome intrinsic resistance to checkpoint blockade in microsatellite stable colorectal Cancer","volume":"13","author":"Kim","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.intimp.2025.115986_bb0645","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"J. Yu, M.D. Green, S. Li, Y. Sun, S.N. Journey, J.E. Choi, S.M. Rizvi, A. Qin, J.J. Waninger, X. Lang","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2025.115986_bb0650","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1234573","article-title":"Functional impairment of infiltrating T cells in human colorectal cancer","volume":"5","author":"Taylor","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.intimp.2025.115986_bb0655","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01719","article-title":"T cell dysfunction in Cancer immunity and immunotherapy","volume":"10","author":"Xia","year":"2019","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115986_bb0660","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in Cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.intimp.2025.115986_bb0670","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1084\/jem.166.4.991","article-title":"Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha","volume":"166","author":"Ranges","year":"1987","journal-title":"J Exp Med"},{"issue":"6_Supplement","key":"10.1016\/j.intimp.2025.115986_bb0675","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1158\/1538-7445.AM2024-1371","article-title":"Abstract 1371: SLAMF9 promotes tumor progression and immunotherapy resistance by reshaping the tumor microenvironment","volume":"84","author":"Fan","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.115986_bb0680","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40164-025-00647-2","article-title":"Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer","volume":"14","author":"Zhang","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.intimp.2025.115986_bb0685","doi-asserted-by":"crossref","first-page":"475","DOI":"10.7150\/ijms.5798","article-title":"Tumor-infiltrating immune cells: triggers for tumor capsule disruption and tumor progression?","volume":"10","author":"Jiang","year":"2013","journal-title":"Int. J. Med. Sci."},{"issue":"19","key":"10.1016\/j.intimp.2025.115986_bb0690","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1039\/D2BM00988A","article-title":"Metformin reprograms tumor microenvironment and boosts chemoimmunotherapy in colorectal cancer","volume":"10","author":"Ni","year":"2022","journal-title":"Biomater. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2025.115986_bb0695","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s10020-021-00402-3","article-title":"Cancer-associated fibroblasts impact the clinical outcome and treatment response in colorectal cancer via immune system modulation: a comprehensive genome-wide analysis","volume":"27","author":"Chen","year":"2021","journal-title":"Mol. Med."},{"issue":"8","key":"10.1016\/j.intimp.2025.115986_bb0700","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer","volume":"5","author":"Reinert","year":"2019","journal-title":"JAMA Oncol."},{"issue":"24","key":"10.1016\/j.intimp.2025.115986_bb0705","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.intimp.2025.115986_bb0710","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2021.07.006","article-title":"Application of T cell receptor (TCR) repertoire analysis for the advancement of cancer immunotherapy","volume":"74","author":"Joshi","year":"2022","journal-title":"Curr. Opin. Immunol."},{"issue":"18","key":"10.1016\/j.intimp.2025.115986_bb0715","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","article-title":"Spatially organized multicellular immune hubs in human colorectal cancer","volume":"184","author":"Pelka","year":"2021","journal-title":"Cell"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925019745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925019745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T16:12:40Z","timestamp":1768061560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925019745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":142,"alternative-id":["S1567576925019745"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115986","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune escape in colorectal cancer: Mechanisms and challenges of immune checkpoint inhibitor resistance","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115986","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115986"}}